Liver transplantation in maple syrup urine disease
- PMID: 10603101
- DOI: 10.1007/pl00014324
Liver transplantation in maple syrup urine disease
Abstract
Maple syrup urine disease (MSUD) is an autosomal recessive disorder. Impaired activity of the branched-chain 2-oxoacid dehydrogenase complex (BCOA-DH) causes accumulation of branched-chain L-amino (BCAA) and 2-oxoacids (BCOA) which may exert neurotoxic effects. Treatment comprises dietary management with strictly reduced quantities of protein and BCAA as well as aggressive intervention during acute neonatal and subsequent metabolic complications. MSUD is regarded as a metabolic disorder with potentially favourable outcome when the patients are kept on a carefully supervised long-term therapy. Up to now, three MSUD patients, exhibiting the classical form of the disease, have received orthotopic whole liver transplantation (OLT). Liver replacement resulted in a clear increase in whole body BCOA-DH activity to at least the level of very mild MSUD variants. These patients no longer require protein restricted diets and the risk of metabolic decompensation during catabolic events is apparently abolished.
Conclusion: Considering the overall expenses, risks, and outcome, however, the benefit of OLT, even in the most severe form of MSUD, may not be significantly different from that of a classical strict dietary management. Thus, OLT appears not to represent a specific option in the treatment in MSUD.
Similar articles
-
Living related versus deceased donor liver transplantation for maple syrup urine disease.Mol Genet Metab. 2016 Mar;117(3):336-43. doi: 10.1016/j.ymgme.2016.01.005. Epub 2016 Jan 12. Mol Genet Metab. 2016. PMID: 26786177
-
Metabolism of branched-chain amino acids in maple syrup urine disease.Eur J Pediatr. 1997 Aug;156 Suppl 1:S62-6. doi: 10.1007/pl00014274. Eur J Pediatr. 1997. PMID: 9266218 Review.
-
Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation.Int J Dev Neurosci. 2023 Oct;83(6):489-504. doi: 10.1002/jdn.10283. Epub 2023 Jun 20. Int J Dev Neurosci. 2023. PMID: 37340513 Review.
-
Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes.Mol Genet Metab. 2020 Mar;129(3):193-206. doi: 10.1016/j.ymgme.2020.01.006. Epub 2020 Jan 16. Mol Genet Metab. 2020. PMID: 31980395
-
Heterozygous liver transplantation for maple syrup urine disease: First European reported case.Pediatr Transplant. 2016 Sep;20(6):846-50. doi: 10.1111/petr.12736. Epub 2016 Jun 30. Pediatr Transplant. 2016. PMID: 27357264
Cited by
-
Liver transplantation from a live donor to a patient with maple syrup urine disease: Two case reports.Turk Pediatri Ars. 2018 Jun 1;53(2):113-116. doi: 10.5152/TurkPediatriArs.2018.3710. eCollection 2018 Jun. Turk Pediatri Ars. 2018. PMID: 30116132 Free PMC article.
-
Outcomes from a Single Transplant Center of 5 Pediatric Cases of Domino Liver Transplantation from Live Donors with Maple Syrup Urine Disease.Ann Transplant. 2023 May 30;28:e939893. doi: 10.12659/AOT.939893. Ann Transplant. 2023. PMID: 37248682 Free PMC article.
-
Liver transplantation for inborn errors of liver metabolism.J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):426-30. doi: 10.1007/s10545-006-0288-x. J Inherit Metab Dis. 2006. PMID: 16763913
-
Adipose transplant for inborn errors of branched chain amino acid metabolism in mice.Mol Genet Metab. 2013 Aug;109(4):345-53. doi: 10.1016/j.ymgme.2013.05.010. Epub 2013 May 30. Mol Genet Metab. 2013. PMID: 23800641 Free PMC article.
-
Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation.Clin Transplant. 2019 Nov;33(11):e13721. doi: 10.1111/ctr.13721. Epub 2019 Oct 6. Clin Transplant. 2019. PMID: 31556146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical